Cited by 137Hedgehog Signaling Pathway StudiesNonmelanoma Skin Cancer StudiesWnt/β-catenin signaling in development and cancer

A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition

Biehs, Brian, Dijkgraaf, Gerrit J. P., Piskol, Robert, Alicke, Bruno, Boumahdi, Soufiane, Peale, Franklin, Gould, Stephen E., de Sauvage, Frederic J.·2018·Nature

Abstract

Despite the efficacy of Hedgehog pathway inhibitors in the treatment of basal cell carcinoma (BCC)1, residual disease persists in some patients and may contribute to relapse when treatment is discontinued 2. Here, to study the effect of the Smoothened inhibitor vismodegib on tumour clearance, we have used a Ptch1-Trp53 mouse model of BCC 3 and found that mice treated with vismodegib harbour quiescent residual tumours that regrow upon cessation of treatment. Profiling experiments revealed that residual BCCs initiate a transcriptional program that closely resembles that of stem cells of the interfollicular epidermis and isthmus, whereas untreated BCCs are more similar to the hair follicle bulge. This cell identity switch was enabled by a mostly permissive chromatin state accompanied by rapid Wnt pathway activation and reprogramming of super enhancers to drive activation of key transcription factors involved in cellular identity. Accordingly, treatment of BCC with both vismodegib and a Wnt pathway inhibitor reduced the residual tumour burden and enhanced differentiation. Our study identifies a resistance mechanism in which tumour cells evade treatment by adopting an alternative identity that does not rely on the original oncogenic driver for survival.

Integrity signals

Registry

Crossref · 10.1038/s41586-018-0596-y

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In vivo models have shown similar drug-tolerant slow-cycling persister cells.

    “In vivo models have shown similar drug-tolerant slow-cycling persister cells.”
  • Drug-tolerant quiescent residual cells in basal cell carcinoma can cause relapse after treatment is stopped.

    “Drug-tolerant quiescent residual cells in basal cell carcinoma (BCC) can cause relapse after treatment is stopped [46,47].”
  • In basal cell carcinoma, comparison of genome-wide chromatin accessibility profiles in drug-naive and residual tumor cells after hedgehog pathway inhibition revealed that regions of increased chromatin accessibility in residual cells were enriched for transcription factor-binding motifs, including SOX family transcription factors that regulate stem and progenitor cell fate.

    “In basal cell carcinoma (BCC), comparison of genome-wide chromatin accessibility profiles in drug-naive and residual tumor cells after hedgehog pathway inhibition revealed that regions of increased chromatin accessibility in residual cells were enriched for transcription factor-binding motifs, including SOX family transcription factors that regulate stem and progenitor cell fate [46].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Biehs, B., Dijkgraaf, G. J. P., Piskol, R., Alicke, B., Boumahdi, S., Peale, F., Gould, S. E., & de Sauvage, F. J.
Affiliations
Genentech (US)
Venue
Nature
Published
2018-10
Volume
562
Issue
7727
Pages
429-433
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2895619213
Cited by
137
References
51
Citations by year
2026: 4 · 2025: 15 · 2024: 15 · 2023: 18 · 2022: 18 · 2021: 31 · 2020: 16 · 2019: 17 · 2018: 3
FWCI
6.05
Type
journal article
Language
en
Open access
closed
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Hedgehog Signaling Pathway Studies
  • Health Sciences › Medicine › Epidemiology › Nonmelanoma Skin Cancer Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
Keywords
basal cell carcinoma, Hedgehog pathway inhibition, vismodegib, Smoothened inhibitors, treatment resistance, residual tumor, super-enhancers, chromatin state, hair follicle bulge, tumor recurrence, epidermal stem cells
MeSH terms
Smoothened Receptor, Epidermal Cells, Anilides, Animals, Basal Cell Carcinoma, Carcinoma, Basal Cell, Cell Differentiation, Humans, Pyridines, Skin Neoplasms, Stem Cells, Signal Transduction, Hair Follicle, Cell Proliferation, Mice, Hedgehog Proteins, Wnt Signaling Pathway

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review